Last Update 16 Jun 26

COLO B: Recent Pullback And New FDA Approval Will Support Future Re Rating

The analyst price target for Coloplast has been revised slightly, with the updated fair value held around DKK 462 as analysts factor in a modestly lower discount rate and only small tweaks to growth and margin assumptions following a series of recent target cuts and one new Buy initiation around DKK 482.

Analyst Commentary

Recent research on Coloplast highlights a split in opinion, with some analysts seeing value after the share price pullback and others focusing on execution risk and margin pressure in their updated targets.

Bullish Takeaways

Bullish analysts point to the recent share selloff as having gone too far relative to Coloplast's fundamentals, which underpins the DKK 482 initiation target and supports the updated fair value around DKK 462.
The DKK 484 target from JPMorgan, despite being reduced from DKK 566, still sits slightly above the current blended fair value, suggesting confidence that the company can execute on its plan over time.
The presence of at least one new Buy rating alongside prior upgrades indicates that some investors see current levels as reasonable for long term exposure, even after a series of target cuts.
Bullish analysts appear comfortable with only modest adjustments to growth and margin assumptions, signaling that they see current operational challenges as manageable within existing forecasts.

Bearish Takeaways

Multiple target reductions, including cuts to DKK 460 and DKK 415 with Hold and Neutral stances, show that several bearish analysts are more cautious on Coloplast's ability to deliver against prior expectations.
The move from higher targets, such as JPMorgan's reduction from DKK 566 to DKK 484, reflects concern that previous valuation levels were too demanding relative to the current execution outlook.
Downgrades and target trims from large institutions, including Goldman Sachs and Nordea, point to a focus on risk around margins, growth consistency and the level of premium investors are willing to pay for the stock.
The cluster of downward revisions over recent months signals that the balance of opinion is still settling, which can keep a lid on Coloplast's valuation until investors gain more clarity on delivery against guidance and cost control.

What’s in the News for Coloplast

Coloplast received FDA approval for Titan Prime, its next generation inflatable penile prosthesis, with a planned phased launch to urologists and health care systems in the US beginning in late 2026. Source: company announcement and recent news reports.
Titan Prime IPP is built with proprietary Bioflex material, described as engineered for greater strength and durability than silicone, and is designed to provide improved flaccid flexibility and consistent outcomes across diverse male anatomies. Source: company announcement.
The company states that around 30 million men in the US experience ongoing difficulty with erections, and positions Titan Prime IPP as an option delivered through a single outpatient procedure for those who do not benefit from medication. Source: company announcement.
Coloplast received an Innovative Technology contract from Vizient for its Biatain Silicone Fit wound care product, following evaluation by Vizient’s client led councils that review products for potential improvements in clinical care, safety, or operations. Source: Vizient client announcement.
Coloplast revised earnings guidance for fiscal year 2025/26, now expecting reported revenue growth in DKK at around 3% and EBIT growth in constant currencies before special items at around 5%, with the Kerecis EBIT margin now assumed around 0%. Source: company guidance update.

Valuation Changes for Coloplast Stock

Fair Value: DKK 461.90 is unchanged, indicating no shift in the central valuation estimate used in this model.
Discount Rate: fallen slightly from 6.33% to 6.22%, which marginally increases the present value assigned to Coloplast's future cash flows in this framework.
Revenue Growth: edged down slightly from 6.49% to 6.48%, reflecting a very small adjustment to the assumed top line expansion in DKK terms.
Net Profit Margin: reduced marginally from 20.10% to 20.07%, pointing to a small change in assumed earnings efficiency on DKK revenue.
Future P/E: eased slightly from 18.35x to 18.33x, implying a very small adjustment to the valuation multiple applied to Coloplast's expected earnings.

4 views

Key Takeaways

Strategic restructuring, targeted innovation, and successful acquisitions are strengthening growth, operational efficiency, and diversification across premium and chronic care segments.
Expanding emerging market presence and user-focused product launches are driving recurring revenues, reducing regional dependence, and positioning Coloplast for sustained long-term momentum.
Intensifying pricing, regulatory, and currency pressures threaten Coloplast's revenue growth, margins, and brand reputation, amid operational risks and dependence on successful product innovation.

Catalysts

About Coloplast

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally.What are the underlying business or industry changes driving this perspective?

The ongoing reorganization into distinct Chronic Care and Acute Care units, with a dedicated R&D function for Chronic Care, is designed to accelerate innovation cycles and improve time-to-market for new products. This is expected to drive higher revenue and operating margins by leveraging user-focused innovation and maximizing manufacturing efficiency.
Robust growth in Chronic Care segments-especially Ostomy and Continence Care-continues to be supported by increasing global incidence of chronic conditions and a growing elderly population, expanding the addressable market and providing a stable foundation for predictable, long-term revenue and earnings growth.
Successful integration and scaling of recent acquisitions like Kerecis, along with the merger of Advanced Wound Dressings and biologics, is expected to enhance Coloplast's competitive positioning in premium wound care markets, supporting margin expansion and revenue diversification as healthcare spending and quality-of-life-focused solutions see secular increases.
Proactive commercial investments in high-growth emerging markets, especially tender-based business in Asia, Eastern Europe, and Latin America, position Coloplast to capture above-market growth, further diversifying revenue streams and reducing over-reliance on mature European regions-likely leading to sustained multi-year revenue and earnings momentum.
The company's user-centric innovation, ongoing product launches (e.g., Luja, SenSura Mio, Provox Life), and pipeline progress (e.g., INTIBIA) are poised to benefit from the accelerating trend toward home-based healthcare and patient-managed solutions, supporting not only top-line growth but also higher recurring revenues and improved net margins over time.

Coloplast Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Coloplast's revenue will grow by 6.5% annually over the next 3 years.
Analysts assume that profit margins will increase from 7.5% today to 20.1% in 3 years time.
Analysts expect earnings to reach DKK 6.8 billion (and earnings per share of DKK 30.22) by about June 2029, up from DKK 2.1 billion today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as DKK7.9 billion.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 18.3x on those 2029 earnings, down from 40.6x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 28.8x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.22%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The implementation of competitive bidding by CMS in the U.S. Chronic Care business could introduce significant pricing pressure starting as early as 2027, affecting approximately 6% of total group sales (50% of the 12% U.S. Chronic Care segment), with the potential for price reductions up to 30%, which would directly threaten revenue and compress net margins.
Regulatory complications and technical requirements unique to certain regions, such as China's strict local standards for wound dressings, have already triggered costly product returns (DKK 80 million impact in 2024-25 and ongoing headwinds into 2025-26), exposing Coloplast to recurring risks of sales interruptions and further negative impacts on revenue and earnings.
Ongoing and recurring product recalls, execution issues, and increasing regulatory scrutiny (both in Europe and China), pose risks to operational efficiency, brand reputation, and long-term profitability due to potential loss of market share to competitors and increased compliance costs.
Fluctuations in foreign exchange rates, particularly the depreciation of the U.S. dollar and emerging market currencies against the Danish krone, have negatively impacted reported revenues, and persistent currency volatility could continue to restrain revenue growth and earnings in future years.
The Acute Care segment is described as more volatile and dependent on innovation compared to the stable but slower-growing Chronic Care segment, implying that failure to deliver successful new launches or manage heightened R&D expenses could result in margin pressure, unpredictable earnings, and overall revenue volatility for the group.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of DKK461.9 for Coloplast based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK600.0, and the most bearish reporting a price target of just DKK380.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be DKK33.9 billion, earnings will come to DKK6.8 billion, and it would be trading on a PE ratio of 18.3x, assuming you use a discount rate of 6.2%.
Given the current share price of DKK380.0, the analyst price target of DKK461.9 is 17.7% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Coloplast?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

COLO B: Executive Team Changes And Chronic Care Strategy Will Drive Outperformance